Ministry of Health of the Russian Federation, with the support of the Interparliamentary Assembly of the CIS Member States, the Government of the Leningrad Region and the Ministry of Industry and Trade of the Russian Federation.
The meeting was moderated by Viсtor Dmitriev, Chairman of the Public Council under the Federal Service for Surveillance in Healthcare (Roszdravnadzor), General Director of the Association of Russian Pharmaceutical Manufacturers.
“The pharmaceutical market of the CIS countries shows dynamic development, the organization of drug availability for citizens is an absolute priority and the focus of attention of the state. The development of partnerships, the scaling up of best manufacturing practices, the creation of a unified legal framework in the field of support for pharmaceutical industries will give a synergistic effect and give a powerful impetus to development,” said Victor Dmitriev.
The active development of the pharmaceutical market of the CIS countries, corresponding to the modern needs of healthcare systems in innovative medical products, can be ensured primarily by the implementation of synergistic development models, cooperation between industries and the transfer of advanced production technologies. The most important elements of development are effective measures of state support for the pharmaceutical industry, models for ensuring sustainable demand for needed drugs, and scalable experience in integrating individual sites.
The session was attended by the Head of the Federal Service for Surveillance in Healthcare (Roszdravnadzor) Alla Samoilova, Director of the Department for the Development of the Pharmaceutical and Medical Industry of the Ministry of Industry and Trade of the Russian Federation Dmitry Galkin, Director General of the Federal State Budgetary Institution «Scientific Center for Expertise of Medicinal Products» of the Ministry of Health of the Russian Federation Valentina Kosenko, President of the Association of Clinical Pharmacologists of St. Petersburg Alexander Khadzhidis, General Director of the Federal State Unitary Enterprise «Moscow Endocrine Plant» Mikhail Fonarev, General Director of PSK Pharma LLC Evgenia Shapiro, Chairman of the Board of SK-Pharmacy LLP (Republic of Kazakhstan) Erkhat Iskaliyev, General Director of LLC «Geropharm» Petr Rodionov, director for strategic development of production assets of JSC «R-Pharm» Elena Sinchenko.
“Cooperation between business and government always gives good results in the manufacturing sector. Especially fast the results of cooperation appear in the pharmaceutical industry. As part of the implementation of the federal target program «Pharma-2020» in Russia, many enterprises have appeared that produce drugs demanded by the medical and patient community, in particular, our company — PSK Pharma. In a short time, the pharmaceutical industry was able to meet the needs of patients in technologically complex, globally recognized effective high-quality drugs, organized their production at a high level. Various grants for research and development contribute to the acceleration of the R&D process and the introduction of necessary drugs to the market, ensuring the drug safety of the country. Companies invest in promising and socially significant areas, create new jobs. In combination, this gives a powerful synergistic effect and stimulates the development of the industry, guarantees reliable drug supply to patients today and in the future. Now the industry has actively taken up the deepening of the production cycle, the creation of its own substances. For example, our enterprise, with the support of the Industrial Development Fund of the Russian Federation and the government of the Moscow Region, is creating an import-substituting production of substances for genetically engineered biotechnological drugs,” said Evgenia Shapiro, General Director of PSK Pharma LLC.
During the meeting, the experts have discussed what the CIS pharmaceutical market is like, what measures are being taken to support the pharmaceutical industry, what is the role of generic drugs in the pharmaceutical market of the CIS countries, what is the role of the transfer of innovative medical technologies, how to ensure demand for needed drugs, what are the advantages that the introduction of a system for labeling and monitoring the movement of drugs gives for the pharmaceutical market, as well as what is the role of cooperation in creating models for transferring innovations and bringing them to the CIS markets.